Recent studies have shown that soluble syndecan-1 (SDC1) serum level is an independent pre-operative predictor of cancer-specific survival in PCa, and SDC1 is associated with more aggressive tumors and a worse prognosis [37]. Here, SDC1 is linked to posterior cortical atrophy.